70 results on '"Obeid, Elias"'
Search Results
2. Updates in the Pathology and Therapy of BRCA Germline–Associated Breast Cancer with a Focus on HER2 Amplification
3. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
4. Table S1, Table S2, Table S3; source file format .docx from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
5. Table S1, Table S2, Table S3; source file format .docx from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
6. Data from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
7. Figure S1, Figure S2, Figure S3; source file format .docx from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
8. Figure S1, Figure S2, Figure S3; source file format .docx from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
9. Data from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
10. Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)
11. Abstract P2-09-08: Impact of race on clinical outcomes among patients with advanced triple negative breast cancer (TNBC) and Germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study
12. Abstract P1-24-02: Genetic variants and tumor microenvironment in inflammatory breast cancer: Clues for targeted therapies
13. Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention
14. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC)
15. Genetic Contribution to Metastatic Prostate Cancer
16. Treatment patterns of older adults with metastatic breast cancer in community practices.
17. Abstract PS10-53: Treatment Patterns and Clinical Outcomes Among Patients with germline BRCA1/2 mutated (gBRCA1/2mut) HER2+ Advanced Breast Cancer (ABC): Results from a US Real-world Study
18. Abstract PS8-16: Differences in the benefit of multi-gene panel (MGP) genetic testing between African American and white women with invasive breast cancer
19. Abstract PS17-27: Molecular evaluation of immunogenicity and genomic alterations in invasive lobular breast cancer
20. Abstract PS11-42: Treatment patterns and clinical outcomes among patients (pts) with HER2- advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): results from a US real-world study
21. Abstract PS10-36: Treatment patterns and clinical outcomes among patients (pts) with HER2- advanced breast cancer (ABC) and somatic BRCA1/2 mutation(s) (sBRCA1/2mut): Results from a US real-world study
22. Abstract PS12-19: Title:peripheral blood immuneimpactsin arandomizedphase iiclinical trial ofprogrammed death 1 (pd-1) blockadecombined with platinum-based chemotherapy in patients with metastatic triple negative breast cancer (mtnbc)
23. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorship
24. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer
25. Germline genetic mutational landscape and characteristics of men with prostate cancer (PCa): A single institution experience.
26. Treatment patterns and clinical outcomes among patients (pts) with HER2+ advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study.
27. Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
28. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment.
29. Abstract P6-08-21: Prevalence of HER2 positivity in germline BRCA 1/2-associated breast cancers (gBRCA1/2-BC)
30. Abstract P5-03-11: Germline and somatic variants in patients with inflammatory breast cancer (IBC) detected using cell-free DNA
31. Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer
32. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
33. Abstract B093: 50 gene breast cancer (BC) RNA subtype classifier and colorectal cancer (CRC) CMS subtype classifier applied to 90 prostate cancer (PC) patients reveals distinct subtype differences
34. Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes
35. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study
36. Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes
37. Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention
38. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
39. Time to surgery and the impact of delay on triple negative breast cancers and other phenotypes.
40. Randomized trial of a text messaging intervention for symptom distress in BCa patients undergoing chemotherapy.
41. Feasibility of perioperative multi-gene panel testing (MGPT) in cancer patients eligible for hereditary genetic evaluation (GE): The PROTECT pilot.
42. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling
43. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
44. The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste
45. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation
46. Multigene Panel Testing and Breast Cancer Risk
47. Are we still adjusting to multigene panel testing? An NCI-designated cancer center's 2-year experience.
48. Knowledge and understanding of genetic test results in men undergoing multigene testing for inherited prostate cancer.
49. Combining chemotherapy and programmed death 1 (PD-1) blockade to induce a T-cell response in patients with metastatic triple negative breast cancer (mTNBC).
50. Abstract B01: Testing a multilevel risk prediction model in high risk men enrolled in a prostate cancer early detection program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.